Raymond James & Associates Lexicon Pharmaceuticals, Inc. Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
A detailed history of Raymond James & Associates transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 10,912 shares of LXRX stock, worth $15,495. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,912
Previous 10,912
-0.0%
Holding current value
$15,495
Previous $18,000
5.56%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding LXRX
# of Institutions
130Shares Held
229MCall Options Held
2.5MPut Options Held
271K-
Artal Group S.A. Luxembourg, N4136MShares$193 Million100.0% of portfolio
-
Siren, L.L.C. New York, NY38.9MShares$55.3 Million2.06% of portfolio
-
Black Rock Inc. New York, NY9.89MShares$14 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.61MShares$13.6 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.83MShares$5.44 Million0.0% of portfolio
About LEXICON PHARMACEUTICALS, INC.
- Ticker LXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 188,726,000
- Market Cap $268M
- Description
- Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...